Should you be interested in the study participation, please, contact us at: rberkovich.research@gmail.com

Current Enrolling Studies

FREXALT (Open to Enrollment):

Phase 3 Study of Frexalimab in Relapsing Multiple Sclerosis

Protocol # EFC 17919

Site: 8400005

Sponsor: Sanofi

ClinicalTrials.gov Identifier: NCT06141473

Link

FREVIVA (Open to Enrollment):

Phase 3 Study of Frexalimab in Progressive Multiple Sclerosis

Protocol # EFC 17504

Site: 8400005

Sponsor: Sanofi

ClinicalTrials.gov Identifier: NCT06141486

Link

REMODEL (Open to Enrollment):

Phase 3 Study of Remibrutinib in Relapsing Multiple Sclerosis

Protocol # CLOU064C12302

Site: 5064

Sponsor: Novartis

ClinicalTrials.gov Identifier: NCT05156281

Link

ZENAS (Open to Enrollment):

Phase 2 Study of Obexelimab in Relapsing Multiple Sclerosis

Protocol # ZB012-02-002

Site: 1003

Sponsor: BioPharma

ClinicalTrials.gov Identifier: NCT06564311

Link

ENSURE-1 (Open to Enrollment):

Phase 3 Study of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Protocol # P3-IMU-838-RMS-01

Site: 100112

Sponsor: Immunic AG

ClinicalTrials.gov Identifier: NCT05134441

Link

Ongoing Studies (enrollment closed)

LTS17043

Phase 3 Study of Tolebrutinib in Relapsing Multiple Sclerosis

Protocol # NCT06372145

Site: 8400059

Sponsor: Sanofi

ClinicalTrials.gov Identifier: NCT06372145

Link

AGNOS

Phase 4 Study of Ofatumumab in Relapsing Multiple Sclerosis

Protocol # COMB157GUS10

Site: 1003

Sponsor: Novartis

ClinicalTrials.gov Identifier: NCT05084638

Link